Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations
Mike Youle(The Royal Free Hospital), José Vera, Anders Blaxhult(The Royal Free Hospital), Adriano Lazzarin(Vita-Salute San Raffaele University), Leopoldo Muñoz(Instituto de Investigación Biosanitaria de Granada), Bonaventura Clotet(Universitat de Vic - Universitat Central de Catalunya), Jacques Reynes(Centre Hospitalier Universitaire de Montpellier), José Ramón Arribas(Hospital Universitario La Paz), Schlomo Staszweski(Goethe University Frankfurt), Martin Fisher(Northwell Health), A Vaccaro(Northwestern University), Colin Kovacs(University of Toronto), Peter Shalit(Research Triangle Park Foundation), Jihad Slim(Saint Michael's Medical Center), Giampiero Carosi(Institute for Scientific Interchange), Debbie Marriott(St Vincent's Hospital Sydney), Gianni Di Perri(Ospedale Amedeo di Savoia), Edwin DeJesus(Orlando Immunology Center), Chris Tsoukas(Montreal General Hospital), Ranjababu Kulasegaram(The King's College), Vicente Estrada(Instituto de Salud Carlos III)
Cited by 23
Related Papers
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653